

Gamma Biosciences Names Terry Pizzie as CEO of Astrea Bioseparations

14 June 2021 | News

Gamma Biosciences, a global life sciences company serving the advanced therapy market, today announced the appointment of Terry Pizzie as Chief Executive Officer (CEO) of operating company Astrea Bioseparations. Pizzie succeeds Dr. Steve Burton, who will remain with the company as President & Chief Scientific Officer.



Pizzie brings more than thirty years of commercial and operating experience in the life sciences and biotechnology sectors, most recently serving as CEO of Cambridge, UK based Horizon Discovery. Prior to joining Horizon, Pizzie held a variety of senior leadership roles at companies including Pacific Biosciences, Genetix, GE Healthcare (Biacore) and Applied Biosystems.

"I am delighted to join the talented team at Astrea and to have the opportunity to lead this exceptional business. Together with Astrea's management team, I will be focused on driving operational and commercial excellence while building out the infrastructure that will allow us to grow with our customers and the market," said Pizzie.

"We are thrilled to welcome Terry to Astrea and thank Steve for his many years of devoted leadership," said Matt Gunnison, President of Gamma Biosciences. "Terry's approach and track record of leading organizations is well aligned with our goal of establishing Astrea as a market leader in advanced therapy manufacturing while remaining true to the company's legacy of scientific and technical excellence."